Established in 1998, Gan & Lee has successfully developed the first domestic biosynthetic human insulin and has launched multiple biosimilar insulin analogue products. The company is engaged in the production and sales of recombinant insulin analog raw materials and injections. With state-of-the-art facilities in Beijing and a US subsidiary in New Jersey, Gan & Lee is committed to expanding its global coverage in the field of diabetes diagnosis and treatment. Additionally, the company is investigating new chemical entities and biologics to treat various diseases, including cardiovascular disease, metabolic disease, and cancer.